Louis Terriou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/440270/publications.pdf

Version: 2024-02-01

88 papers 3,962 citations

147566 31 h-index 60 g-index

101 all docs

101 docs citations

times ranked

101

4932 citing authors

#	Article	IF	CITATIONS
1	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	3.8	566
2	Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood, 2008, 112, 3099-3106.	0.6	313
3	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	0.6	232
4	Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2015, 373, 1032-1039.	13.9	201
5	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Advances, 2017, 1, 2742-2755.	2.5	151
6	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood, 2014, 124, 3228-3236.	0.6	142
7	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	1.7	129
8	Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood, 2009, 114, 719-722.	0.6	125
9	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica, 2012, 97, 1666-1673.	1.7	110
10	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus noâ€treatment study. American Journal of Hematology, 2016, 91, 366-370.	2.0	110
11	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmunity Reviews, 2017, 16, 743-749.	2.5	101
12	The Lymphoid Variant of Hypereosinophilic Syndrome. Medicine (United States), 2014, 93, 255-266.	0.4	98
13	Azacitidine for patients with Vacuoles, E1 Enzyme, Xâ€linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. British Journal of Haematology, 2022, 196, 969-974.	1.2	85
14	A randomized and doubleâ€blind controlled trial evaluating the safety and efficacy of rituximab for warm autoâ€mmune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology, 2017, 92, 23-27.	2.0	84
15	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood, 2016, 128, 1625-1630.	0.6	78
16	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	0.6	76
17	<i><scp>MYD</scp>88</i> L265P mutation contributes to the diagnosis of Bing Neel syndrome. British Journal of Haematology, 2014, 167, 506-513.	1.2	71
18	Clinical characteristics, management and outcome of COVIDâ€19â€nssociated immune thrombocytopenia: a French multicentre series. British Journal of Haematology, 2020, 190, e224-e229.	1.2	68

#	Article	IF	CITATIONS
19	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase $1b/2$ studies. Blood Advances, 2018, 2, 2176-2185.	2.5	65
20	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 2006, 20, 2067-2070.	3.3	64
21	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 2018, 103, 212-220.	1.7	62
22	Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma. Clinical Cancer Research, 2014, 20, 3254-3260.	3.2	59
23	Longâ€ŧerm safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITPâ€ritux. American Journal of Hematology, 2019, 94, 1314-1324.	2.0	55
24	Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia, 2013, 27, 252-255.	3.3	42
25	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood, 2020, 136, 3056-3061.	0.6	42
26	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology, 2018, 57, 1432-1438.	0.9	38
27	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica, 2015, 100, 1086-95.	1.7	37
28	Epidemiology, clinical picture and longâ€ŧerm outcomes of <i>FIP1L1â€PDGFRA</i> â€positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	2.0	37
29	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investigational New Drugs, 2015, 33, 423-431.	1.2	33
30	Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood, 2015, 126, 1643-1650.	0.6	32
31	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. Autoimmunity Reviews, 2017, 16, 903-910.	2.5	32
32	Cerebral Venous Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Medicine (United States), 2015, 94, e362.	0.4	30
33	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. Frontiers in Medicine, 2017, 4, 149.	1.2	30
34	Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Medicine, 2017, 43, 1613-1625.	3.9	26
35	Value of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies. Frontiers in Immunology, 2017, 8, 1862.	2.2	26
36	Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Frontiers in Immunology, 2019, 10, 1489.	2.2	24

#	Article	lF	CITATIONS
37	Reemergence of Splenectomy for ITP Second-line Treatment?. Annals of Surgery, 2016, 264, 772-777.	2.1	23
38	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. American Journal of Hematology, 2016, 91, E499-E501.	2.0	20
39	Safety of antiâ€SARSâ€CoVâ€2 vaccination for patients with immune thrombocytopenia. British Journal of Haematology, 2021, 195, 703-705.	1.2	20
40	Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 2019, 104, 256-262.	1.7	19
41	Temsirolimus in the treatment of mantle cell lymphoma. Current Opinion in Oncology, 2013, 25, S1-S12.	1.1	18
42	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Reports Medicine, 2020, 1, 100158.	3.3	18
43	Disseminated Infection Caused by <i>Francisella philomiragia </i> , France, 2014. Emerging Infectious Diseases, 2012, 21, 2260-2261.	2.0	17
44	Radioimmunotherapy (90Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab. American Journal of Transplantation, 2015, 15, 1976-1981.	2.6	16
45	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. Haematologica, 2018, 103, e103-e105.	1.7	16
46	Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplantation, 2019, 54, 1161-1163.	1.3	16
47	Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases. Clinical Infectious Diseases, 2017, 65, 328-331.	2.9	15
48	Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AML. Leukemia, 2008, 22, 655-657.	3.3	12
49	Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens. Annals of Hematology, 2006, 85, 711-716.	0.8	11
50	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. American Journal of Hematology, 2021, 96, E43-E46.	2.0	11
51	Are there any additional mechanisms for haemolysis in HELLP syndrome?. Thrombosis Research, 2016, 142, 40-43.	0.8	10
52	Coexistence of rheumatoid arthritis and TEMPI syndrome: New insight in microangiogenic-related diseases. Joint Bone Spine, 2016, 83, 587-588.	0.8	10
53	Extensive levamisole-induced vasculitis. Clinical and Experimental Dermatology, 2017, 42, 413-415.	0.6	10
54	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. European Respiratory Journal, 2017, 49, 1700178.	3.1	9

#	Article	IF	CITATIONS
55	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. Current Research in Translational Medicine, 2018, 66, 83-86.	1.2	9
56	A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. Blood, 2013, 122, 4397-4397.	0.6	9
57	Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia—an unusual association: another cause of cytopenia in PNH. Annals of Hematology, 2015, 94, 1759-1760.	0.8	7
58	Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clinical Rheumatology, 2019, 38, 1501-1511.	1.0	7
59	Assessment of T-cell polarization onÂthe basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1110-1114.e2.	2.0	7
60	Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature. Haematologica, 2020, 105, e333-e336.	1.7	7
61	The Bruton's Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). Blood, 2014, 124, 3328-3328.	0.6	7
62	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	2.0	7
63	C/EBPA methylation is common in T-ALL but not in MO AML. Blood, 2009, 113, 1864-1866.	0.6	6
64	Persistent viral DNA detection in blood after primary herpes simplex 1 infection revealed by hepatitis with hemophagocytic syndrome. Journal of Clinical Virology, 2015, 69, 101-103.	1.6	6
65	Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma. Melanoma Research, 2017, 27, 377-379.	0.6	6
66	Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: A study of 25 consecutive patients and a literature review. Leukemia and Lymphoma, 2007, 48, 321-329.	0.6	5
67	The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL Journal of Clinical Oncology, 2014, 32, 8553-8553.	0.8	5
68	Risk factors for severe neonatal thrombocytopenia in cases of maternal immune thrombocytopenia. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 985-991.	0.7	4
69	Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. Bone Marrow Transplantation, 2014, 49, 1492-1497.	1.3	3
70	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. Journal of Clinical Rheumatology, 2019, 25, e40-e42.	0.5	3
71	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. Journal of Clinical Medicine, 2021, 10, 1162.	1.0	3
72	Correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARSâ€CoVâ€⊋ vaccine. British Journal of Haematology, 2021, 194, e93-e95.	1.2	3

#	Article	IF	CITATIONS
73	A Multicenter Study Evaluating the Safety of Romiplostim at Maximal Dosage for Emergency Bleeding Situations in Immune Thrombocytopenia. Blood, 2016, 128, 2541-2541.	0.6	3
74	Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort. Blood, 2016, 128, 2542-2542.	0.6	3
75	Detection of Non-Hodgkin's Lymphoma in ovarian cortex pieces during the process of cryopreservation. Journal of Assisted Reproduction and Genetics, 2014, 31, 1251-1255.	1.2	2
76	Safety and Efficacy Of Rituximab In adult's Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry. Blood, 2013, 122, 450-450.	0.6	2
77	Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 4393-4393.	0.6	2
78	A Multicenter, Case-Control Study Evaluating the Characteristics and Outcome of ITP Patients Refractory to, Rituximab, Splenectomy and Both TPO Receptor Agonists. Blood, 2015, 126, 3460-3460.	0.6	2
79	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. Blood, 2012, 120, 3643-3643.	0.6	2
80	Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	2.0	2
81	Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia, 2012, 26, 2552-2554.	3.3	1
82	OP0184â€Clinical Spectrum and Therapeutic Management of Systemic Lupus Erythematosus-Associated Macrophage Activation Syndrome. Data from A French Nationwide Study of 81 Episodes in 67 Adult Patients. Annals of the Rheumatic Diseases, 2016, 75, 126.2-127.	0.5	1
83	Reply to Gilchrist et al. and to Musher. Clinical Infectious Diseases, 2018, 66, 637-638.	2.9	1
84	Allogeneic Hematopoietic Stem Cell Transplantation in Paroxysmal Nocturnal Hemoglobinuria: A Transplant Versus No Transplant Matched Comparison Study On Behalf of the Severe Aplastic Anemia Working Party (SAA WP) of the European Group for Blood and Marrow Transplantation (EBMT) Group and the French Society of Hematology (SFH). Blood, 2011, 118, 2403-2403.	0.6	1
85	Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. Blood. 2015. 126. 1985-1985.	0.6	1
86	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults. Blood, 2015, 126, 3338-3338.	0.6	1
87	Traitement de maintenance des lymphomes malins non hodgkiniens. Oncologie, 2011, 13, 543-547.	0.2	0
88	Nilotinib as Salvage Therapy In Patients with Chronic Graft Versus Host Disease. Blood, 2010, 116, 2329-2329.	0.6	0